Abbott Laboratories (NYSE:ABT) saw an upside of 0.11% to $117.01 after adding $0.13 on Tuesday. The 5-day average trading volume is 4,385,910 shares of the company’s common stock. It has gained $119.33 in the past week. An average of 5,199,317 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,459,265.
ABT’s 1-month performance is -9.25% or -$11.89 on its low of $114.40 reached on 10/06/21. The company’s shares have touched a 52-week low of $103.13 and high of $129.70, with the stock’s rally to the 52-week high happening on 09/13/21. YTD, ABT has achieved 6.75% or $7.43. However, the current price is down -9.78%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 08, 34 days have gone by since the last insider trading activity for Abbott Laboratories (ABT). PEDERSON MICHAEL J (SENIOR VICE PRESIDENT) most recently sold 23,008 shares at $129.05 per share on Sep 08. This transaction cost the insider $2,969,173. SENIOR VICE PRESIDENT, WOODGRIFT RANDEL WILLIAM, sold 6,350 shares at a price of $129.00 on Sep 03. Then, on Sep 02, EXECUTIVE VICE PRESIDENT Wainer Andrea F sold 9,500 shares at a price of $127.50 per share. This transaction amounted to $1,211,250.
The company’s PE ratio for the last five years has touched a high of 254.16 and a low of 30.50. ABT stock has a beta of 0.65. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.13 while the price-to-book (PB) in the most recent quarter is 6.15, with the price to cash flow ratio at 35.82.
Abbott Laboratories pays an annual dividend of $1.80 per share. Its dividend yield is 1.54% and the payout ratio is 45.10%. ABT paid $0.45 a share compared with prior rate of $0.45, down 0.0% from last year’s. The company has boosted its dividend for the last 49 consecutive years with the latest dividend increase of $0.09 reported on Friday December 11 2020. Measured over the last 3 years, the Dividend has been growing by 35.85% yearly.
It is projected that Abbott Laboratories’s next ex-dividend date will be on 14-Oct-2021. ABT is expected to distribute $0.45 as its next dividend.
Abbott Laboratories’s quick ratio for the period ended June 29 was 1.40, with the current ratio over the same period at 1.80 meaning that ABT stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.52, while the total debt to equity was 0.55. In terms of profitability, the gross margin trailing 12 months is 55.80%. The trailing 12-month EBITDA margin is 24.90% while for the period ending June 29; Abbott Laboratories’s operating margin was 18.60%. The firm’s gross profit as reported stood at $19.61 billion against revenue of $34.61 billion.
For the quarterly period ending June 29 this year, Abbott Laboratories’s cash and short-term investments amounted to $286.0 million against total debt of $18.5 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 28.32% to $10.22 billion, while revenue of $10.46 billion was -2.28% off the previous quarter. Analysts expected ABT to announce $1.02 per share in earnings in its latest quarter, but it posted $1.17, representing a 14.70% surprise. EBITDA for the quarter stood at more than $2.27 billion. ABT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 39.24 billion, with total debt at $18.5 billion. Shareholders hold equity totaling $1.77 billion
Let’s look briefly at Abbott Laboratories (ABT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 33.23% to suggest the stock is trending Neutral, with historical volatility in this time period at 13.95%.
The stock’s 5-day moving average is $117.32, reflecting a +0.89% or $1.04 change from its current price. ABT is currently trading -7.98% above its 20-day SMA, -0.75% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -3.31% and +7.90% respectively.
Stochastic %K and %D was 25.23% and 26.00% and the average true range (ATR) pointed at 2.07. The RSI (14) points at 34.54%, while the 14-day stochastic is at 21.88% with the period’s ATR at 2.04. The stock’s 9-day MACD Oscillator is pointing at 0.36 and -1.30 on the 14-day charts.
In the most recent analyst report for Abbott Laboratories (NYSE: ABT), Barclays launched coverage with an Overweight rating. Analysts offering their rating for ABT stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate ABT as a “sell,”, while 3 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 5 rates the stock as overweight while 14 have offered a “buy” rating.
What is ABT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $109.00 and a high of $140.00, with their median price target at $133.00. Looking at these predictions, the average price target given by analysts is for Abbott Laboratories (ABT) stock is $130.57.